scholarly journals Regulation of ABC transporters by hypoxia in HK‐2 human proximal tubule epithelial cells

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Git Chung ◽  
Colin Douglas Brown
2020 ◽  
Vol 21 (16) ◽  
pp. 5825 ◽  
Author(s):  
Amanda Kristiansson ◽  
Sara Davidsson ◽  
Maria E. Johansson ◽  
Sarah Piel ◽  
Eskil Elmér ◽  
...  

Oxidative stress is associated with many renal disorders, both acute and chronic, and has also been described to contribute to the disease progression. Therefore, oxidative stress is a potential therapeutic target. The human antioxidant α1-microglobulin (A1M) is a plasma and tissue protein with heme-binding, radical-scavenging and reductase activities. A1M can be internalized by cells, localized to the mitochondria and protect mitochondrial function. Due to its small size, A1M is filtered from the blood into the glomeruli, and taken up by the renal tubular epithelial cells. A1M has previously been described to reduce renal damage in animal models of preeclampsia, radiotherapy and rhabdomyolysis, and is proposed as a pharmacological agent for the treatment of kidney damage. In this paper, we examined the in vitro protective effects of recombinant human A1M (rA1M) in human proximal tubule epithelial cells. Moreover, rA1M was found to protect against heme-induced cell-death both in primary cells (RPTEC) and in a cell-line (HK-2). Expression of stress-related genes was upregulated in both cell cultures in response to heme exposure, as measured by qPCR and confirmed with in situ hybridization in HK-2 cells, whereas co-treatment with rA1M counteracted the upregulation. Mitochondrial respiration, analyzed with the Seahorse extracellular flux analyzer, was compromised following exposure to heme, but preserved by co-treatment with rA1M. Finally, heme addition to RPTE cells induced an upregulation of the endogenous cellular expression of A1M, via activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-pathway. Overall, data suggest that A1M/rA1M protects against stress-induced damage to tubule epithelial cells that, at least partly, can be attributed to maintaining mitochondrial function.


Virology ◽  
2016 ◽  
Vol 492 ◽  
pp. 66-72 ◽  
Author(s):  
Linbo Zhao ◽  
Anthony T. Marciano ◽  
Courtney R. Rivet ◽  
Michael J. Imperiale

2015 ◽  
Vol 30 (10) ◽  
pp. 1674-1683 ◽  
Author(s):  
Sandeep Sampangi ◽  
Xiangju Wang ◽  
Kenneth W. Beagley ◽  
Travis Klein ◽  
Sadia Afrin ◽  
...  

2021 ◽  
Vol 22 (6) ◽  
pp. 2809
Author(s):  
Paul E. Squires ◽  
Gareth W. Price ◽  
Ulrik Mouritzen ◽  
Joe A. Potter ◽  
Bethany M. Williams ◽  
...  

Chronic kidney disease (CKD) is a global health problem associated with a number of comorbidities. Recent evidence implicates increased hemichannel-mediated release of adenosine triphosphate (ATP) in the progression of tubulointerstitial fibrosis, the main underlying pathology of CKD. Here, we evaluate the effect of danegaptide on blocking hemichannel-mediated changes in the expression and function of proteins associated with disease progression in tubular epithelial kidney cells. Primary human proximal tubule epithelial cells (hPTECs) were treated with the beta1 isoform of the pro-fibrotic cytokine transforming growth factor (TGFβ1) ± danegaptide. qRT-PCR and immunoblotting confirmed mRNA and protein expression, whilst a cytokine antibody array assessed the expression/secretion of proinflammatory and profibrotic cytokines. Carboxyfluorescein dye uptake and ATP biosensing measured hemichannel activity and ATP release, whilst transepithelial electrical resistance was used to assess paracellular permeability. Danegaptide negated carboxyfluorescein dye uptake and ATP release and protected against protein changes associated with tubular injury. Blocking Cx43-mediated ATP release was paralleled by partial restoration of the expression of cell cycle inhibitors, adherens and tight junction proteins and decreased paracellular permeability. Furthermore, danegaptide inhibited TGFβ1-induced changes in the expression and secretion of key adipokines, cytokines, chemokines, growth factors and interleukins. The data suggest that as a gap junction modulator and hemichannel blocker, danegaptide has potential in the future treatment of CKD.


2012 ◽  
Vol 28 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Andrew J. Kassianos ◽  
Sandeep Sampangi ◽  
Xiangju Wang ◽  
Kathrein E. Roper ◽  
Ken Beagley ◽  
...  

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
J. Jansen ◽  
I. E De Napoli ◽  
M. Fedecostante ◽  
C. M. S. Schophuizen ◽  
N. V. Chevtchik ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document